XML 55 R13.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Business Combination | 12 Months Ended
--- | ---
Dec. 31, 2021
Business Combination |
Business Combination. | Note 6 – Business Combination BioArkive Acquisition On December 22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (“BioArkive”), for a market value of $8.75 million. BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline. In connection with the acquisition, the Company has assumed the obligations under BioArkive’s three lease agreements. The purchase price was paid by Immuneering through the issuance of an aggregate of 379,635 shares of Immuneering’s Class A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing date. The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7,875,000. Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock. BioArkive provided contract services to the Company. Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to $4,548,780 in 2021 through date of the acquisition and $2,744,051 in 2020. As of December 31, 2020, $279,153 was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets. Assets Acquired and Liabilities Assumed at Fair Value The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December 31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill. Intangible Assets The estimated fair value of the intangible assets was determined using the relief from royalty approach. Goodwill Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes. Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company’s operations. ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Preliminary Valuation |  | Weighted Average Life
Cash | ​ | $ | 70,348 | ​ | ​ | ​
Other currents assets | ​ | ​ | 225,790 | ​ | ​ | ​
Other long term assets | ​ | ​ | 87,796 | ​ | ​ | ​
Property, plant and equipment, net | ​ | ​ | 727,539 | ​ | ​ | ​
Right of use assets | ​ | ​ | 4,824,700 | ​ | ​ | ​
Intangible asset | ​ | ​ | ​ | ​ | ​ | ​
Technology | ​ | ​ | 439,000 | ​ | ​ | 15 years
Goodwill | ​ | ​ | 6,701,726 | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Total assets acquired | ​ | ​ | 13,076,899 | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable, accrued expenses and other liabilities | ​ | ​ | 69,714 | ​ | ​ | ​
Deferred tax liabilities | ​ | ​ | 307,485 | ​ | ​ | ​
Lease liabilities | ​ | ​ | 4,824,700 | ​ | ​ | ​
Net assets acquired | ​ | $ | 7,875,000 | ​ | ​ | ​
​

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration